Current perspective on the role of the interleukin-23/interleukin-17 axis in inflammation and disease (chronic arthritis and psoriasis) by Cauli A, Piga M, Floris A, Mathieu A

Get full text

Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence by Iannone F, Conti F, Cauli A, Farina A, Caporali R

Get full text

Clinical potential of apremilast in the treatment of psoriatic arthritis by Cauli A, Porru G, Piga M, Vacca A, Dessole G, Mathieu A

Get full text

THE ARTHRITIS-ASSOCIATED HLA-B(star)27:05 FORMS MORE CELL SURFACE B27 DIMER AND FREE HEAVY CHAIN LIGANDS FOR KIR3DL2 AND LILRB2 IMMUNORECEPTORS THAN HLA(star)B27:09 by Shaw, J, Hatano, H, Cauli, A, Giles, J, McHugh, K, Mathieu, A, Bowness, P, Kollnberger, S

Enhanced Expression of KIR3DL2 in Natural Killer and CD3/CD4 Positive T Cells of Ankylosing Spondylitis Patients Compared to HLA-B*2705 or B*2709 Healthy Subjects by Cauli, A, Dessole, G, Porru, G, Vacca, A, Piga, M, Ibba, V, Garau, P, Kollnberger, S, Mathieu, A

Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biolo... by Lliso, G, Humby, F, Lewis, M, Nerviani, A, Mauro, D, Rivellese, F, Kelly, S, Hands, R, Bene, F, Ramamoorthi, N, Hackney, JA, Cauli, A, Choy, EH, Filer, A, Taylor, PC, McInnes, I, Townsend, MJ, Pitzalis, C

The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLA-B*27:09. by Cauli, A, Shaw, J, Giles, J, Hatano, H, Rysnik, O, Payeli, S, McHugh, K, Dessole, G, Porru, G, Desogus, E, Fiedler, S, Hölper, S, Carette, A, Blanco-Gelaz, M, Vacca, A, Piga, M, Ibba, V, Garau, P, La Nasa, G, López-Larrea, C, Mathieu, A, Renner, C, Bowness, P, Kollnberger, S

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients by Humby, F, Lewis, M, Ramamoorthi, N, Hackney, J, Barnes, M, Bombardieri, M, Setiadi, F, Kelly, S, Bene, F, Di Cicco, M, Riahi, S, Rocher-Ros, V, Ng, N, Lazorou, I, Hands, R, Van Der Heijde, D, Landewe, R, van Der Helm-Van Mil, A, Cauli, A, McInnes, I, Buckley, C, Choy, E, Taylor, P, Townsend, M, Pitzalis, C

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): A stratified, biopsy-driven, multi-centre, randomised, open label, controll... by Humby, F, Durez, P, Buch, MH, Lewis, M, Rizvi, H, Rivellese, F, Nerviani, A, Giorli, G, Mahto, A, Montecucco, C, Lauwerys, B, Ng, N, Ho, P, Bombardieri, M, Romão, VC, Verschueren, P, Kelly, S, Sainaghi, PP, Gendi, N, Dasgupta, B, Cauli, A, Reynolds, P, Cañete, JD, Moots, R, Taylor, P, Edwards, CJ, Isaacs, J, Sasieni, P, Choy, E, Pitzalis, C

Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes by Lewis, MJ, Barnes, MR, Blighe, K, Goldmann, K, Rana, S, Hackney, J, Ramamoorthi, N, John, CR, Watson, D, Kummerfeld, SK, Hands, R, Riahi, S, Rocher-Ros, V, Rivellese, F, Humby, F, Kelly, S, Bombardieri, M, Ng, N, Dicicco, M, Van Der Heijde, D, Landewe, R, Van Der Helm-Van Mil, A, Cauli, A, McInnes, IB, Buckley, CD, Choy, E, Taylor, PC, Townsend, MJ, Pitzalis, C

Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomise... by Rivellese, F, Nerviani, A, Giorli, G, Warren, L, Jaworska, E, Bombardieri, M, Lewis, MJ, Humby, F, Pratt, AG, Filer, A, Gendi, N, Cauli, A, Choy, E, McInnes, I, Durez, P, Edwards, CJ, Buch, MH, Gremese, E, Taylor, PC, Ng, N, Cañete, JD, Raizada, S, McKay, ND, Jadon, D, Sainaghi, PP, Stratton, R, Ehrenstein, M, Ho, P, Pereira, JP, Dasgupta, B, Gorman, C, Galloway, J, Chinoy, H, van der Heijde, D, Sasieni, P, Barton, A, Pitzalis, C